# Leuvectin Followed By Surgery in Treating Patients With Stage II or Stage III Prostate Cancer

> **NCT00004050** · PHASE2 · TERMINATED · sponsor: **Vical** · enrollment: 13 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **BIOLOGICAL:** Leuvectin

## Key facts

- **NCT ID:** NCT00004050
- **Lead sponsor:** Vical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 1999-06
- **Primary completion:** 2003-04
- **Final completion:** 2003-04
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Development in prostate cancer indication halted
- **Last updated:** 2014-07-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004050

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004050, "Leuvectin Followed By Surgery in Treating Patients With Stage II or Stage III Prostate Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00004050. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*